LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

Kodu・Aktsiate loetelu・VolitionRX Ltd

VolitionRX Ltd

Suletud

0.27 -6.9

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.26

Max

0.29

Põhinäitajad
By Trading Economics
Sissetulek	936K -5.4M
Müük	221K 627K
Kasumimarginaal	-857.414
Töötajad	75
EBITDA	1.3M -4.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+675.86% upside

Turustatistika
By TradingEconomics
Turukapital	-11M 36M
Eelmine avamishind	7.17
Eelmine sulgemishind	0.27

VolitionRX Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. dets 2025, 23:21 UTC

Tulu

Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3. dets 2025, 23:14 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3. dets 2025, 22:01 UTC

Suurimad hinnamuutused turgudel

Costco Wholesale Reports Higher Monthly Sales

3. dets 2025, 21:38 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3. dets 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3. dets 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. dets 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3. dets 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3. dets 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3. dets 2025, 23:10 UTC

Tulu

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3. dets 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3. dets 2025, 23:06 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5M

3. dets 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3. dets 2025, 22:20 UTC

Tulu

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3. dets 2025, 22:19 UTC

Tulu

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3. dets 2025, 22:17 UTC

Tulu

Salesforce Working to Add Voice to Agentforce, CEO Says

3. dets 2025, 22:16 UTC

Tulu

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3. dets 2025, 22:15 UTC

Tulu

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3. dets 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3. dets 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. dets 2025, 21:49 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:23 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3. dets 2025, 21:19 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:06 UTC

Tulu

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:04 UTC

Tulu

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3. dets 2025, 21:04 UTC

Tulu

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3. dets 2025, 21:03 UTC

Tulu

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Võrdlus sarnastega

Hinnamuutus

VolitionRX Ltd Prognoos

Hinnasiht

By TipRanks

675.86% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD 675.86%

Kõrge 3 USD

Madal 1.5 USD

Põhineb 4 Wall Streeti analüütiku instrumendi VolitionRX Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi VolitionRX Ltd aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.